About Curodont™
Curodont™, with its main component the self-assembling peptide P11-4, is the first product for which credentis has obtained market approval (CE-label).
Curodont™ provides dentists with a novel technology to regenerate rather than repair carious and similar tooth lesions. Applied to a small lesion, Curodont™ forms a scaffold of small fibres within the lesion around which new enamel or dentin can form and grow. Ideally, within several weeks the lesion will regenerate without the use of burr or filler.
The market approval enables us to verify the encouraging data from the first clinical study in larger studies, to further optimise the application, and build reference centres for the use of Curodont™: “We want to develop not only a product, but aim at establishing a novel approach to caries treatment within the dental practice. Curodont™ has great potential in the treatment of dental caries!” explains Dominik Lysek. The ultimate goal is to prevent caries by frequent dental recalls and regenerative treatments by dentists and dental hygienists.
About credentis ag
credentis has its headquarters in the Technopark Aargau Switzerland, Windisch; it has already won the support of Genilem and presented itself successfully at various events including the Argovian and Swiss Equity Fairs and was one of Swiss Venture Leaders 2011.
CEO Dominik Lysek and CTO Michael Hug have expert knowledge in medicinal technology and a strong network in the dental industry. Dr. Werner Berner (member of the board) and Dr. Erich Platzer (chairman of the board), both members of the StartAngels Network, perfectly complement the know-how of the management and contribute to the success of the young company with their expert industry knowledge.
Contact: Dr. Dominik Lysek, CEO, tel +41 56 560 2044; info@credentis.com
